ACC's October Board of Trustees (BOT) meeting was rich with strategic dialogue and forward-looking initiatives that reflect our shared commitment to advancing cardiovascular care and strengthening the ...

Marijuana is now legal in many places, but is it safe? Two new studies add to mounting evidence that people who use cannabis are more likely to suffer a heart attack than people who do not use the ...

Semaglutide, a medication initially developed for type 2 diabetes and obesity, significantly improves symptoms in men and women with a common type of heart failure that has had few therapeutic options ...

In this week’s View, Dr. Eagle highlights several important studies presented at the recent American Heart Association Scientific Sessions. The OCEAN Trial on antithrombotic and stroke prevention in ...

Findings from the PREVUE-VALVE study presented at TCT 2025 shed light on the prevalence of valvular heart disease (VHD) and its subtypes among older Americans, as well as the influence of age, sex, ...

A new nasal spray form of bumetanide may reduce the tissue swelling caused by heart failure (HF) as effectively as the standard oral and intravenous formulations of the loop diuretic, based on ...

Get coverage of important new developments in cardiology ...

The newest clinical guideline released by the ACC and American Heart Association (AHA), in collaboration with seven other societies, provides updated recommendations for perioperative cardiovascular ...

In this episode, Clyde W. Yancy, MD, MSc, MACC, and Leslie L. Davis, NP, PhD, FACC, discuss the 2022 AHA/ACC/HFSA Guideline for the Management of HF and where to consider newer treatments with ...

Mavacamten did not significantly improve exercise capacity as assessed by peak oxygen uptake or improve patient-reported health status compared with placebo in patients with symptomatic nonobstructive ...

Digitoxin in addition to guideline-directed medical therapy, reduced the risk of a composite of all-cause death and hospitalization for worsening heart failure (HF) among patients with advanced HF and ...

Ultrashort dual antiplatelet therapy (DAPT) following percutaneous coronary intervention for acute coronary syndrome is safe. A lower dose (5 mg) of prasugrel at 1 month led to lower bleeding rates ...